Growth through leadership Genpro has appointed senior clinical and sales leadership in 2021-2022, signaling a sharpened focus on expanding medical writing, biometrics, and sales channels. This presents an opportunity to align solutions with their strategic growth areas and leverage executive relationships for larger multi-year engagements.

Biometrics and analytics The company positions itself as a global biometrics CRO with advanced data analytics, automation, and life sciences intelligence. Sales opportunities exist in expanding their pharmacovigilance, clinical data analytics, and automated reporting capabilities to accelerate drug development timelines for pharma and biotech clients.

Tech-enabled ops A tech stack that includes SAS, Power BI, Kubernetes, Salesforce, Jira and Trello indicates maturity in data-driven operations and project management. This suggests potential for selling integrated analytics, cloud-based data workflows, and collaboration tooling enhancements to improve efficiency and quality.

Global write and oversight Genpro serves medical affairs, medical & scientific writers, and pharmacovigilance professionals, offering an avenue to upsell regulated content creation, medical writing accelerators, and safety reporting solutions to pharma and device companies seeking faster, compliant deliverables.

Early-stage scale With under one million annual revenue and a small employee base, Genpro appears poised for scale and strategic partnerships. Target clients could include mid-market pharma services firms looking to augment biometrics, data analytics, and regulatory affairs capabilities as they expand portfolios.